Evidence map›Paper›PMID 37037812›Full record

ArticleSignal transduction and targeted therapy2023

The protective nasal boosting of a triple-RBD subunit vaccine against SARS-CoV-2 following inactivated virus vaccination.

Jingyi Yang, Mei-Qin Liu, Lin Liu, Xian Li, Mengxin Xu, Haofeng Lin, Min Li, Huimin Yan, Yao-Qing Chen, Zheng-Li Shi

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jingyi Yang *Vaccine and Immunology Research Center, Translational Medical Research Institute, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Mei-Qin Liu *Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
Lin Liu *School of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
Xian Li *Vaccine and Immunology Research Center, Translational Medical Research Institute, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Mengxin XuSchool of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, Guangdong, 518107, China.
Haofeng LinWuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
Min LiVaccine and Immunology Research Center, Translational Medical Research Institute, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China.
Huimin YanVaccine and Immunology Research Center, Translational Medical Research Institute, Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, China. yanhuimin@shphc.org.cn.ORCID 0000-0002-7243-8429
Yao-Qing ChenSchool of Public Health (Shenzhen), Shenzhen Campus of Sun Yat-sen University, Sun Yat-sen University, Shenzhen, Guangdong, 518107, China. chenyaoqing@mail.sysu.edu.cn.ORCID 0000-0002-4659-1550
Zheng-Li ShiWuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China. zlshi@wh.iov.cn.ORCID 0000-0001-8089-163X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19SARS-CoV-2COVID-19 VaccinesHumansCOVID-19 Vaccines

Identifiers

PMID37037812
PMCPMC10086003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.